4.0 Review

Standard Therapy for Glioblastoma-A Review of Where We Are

Journal

NEUROLOGIA MEDICO-CHIRURGICA
Volume 50, Issue 9, Pages 713-719

Publisher

JAPAN NEUROSURGICAL SOC
DOI: 10.2176/nmc.50.713

Keywords

glioblastoma; standard therapy; chemotherapy; temozolomide; clinical trial

Ask authors/readers for more resources

Glioblastoma is the most common primary malignant brain tumor in adults and is a challenging disease to treat. The current standard therapy includes maximal safe surgical resection, followed by a combination of radiation and chemotherapy with temozolomide. However, recurrence is quite common, so we continue to search for more effective treatments both for initial therapy and at the time of recurrence. This article will review the current standard of care and recent advances in therapy for newly-diagnosed and recurrent glioblastomas, based on the most authoritative guidelines, the National Cancer Institute's comprehensive cancer database Physician Data Query (PDQ (R)), and the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (TM) for central nervous system cancers (V.1.2010), to elucidate the current position and in what direction we are advancing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available